Does the year 2025 mark a true, tangible shift toward biomarker-driven precision medicine for metastatic hormone-sensitive prostate cancer (mHSPC)?

Credit available for this activity expires: 11/18/26
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/latest-advances-mhspc-update-berlin-2025-2025a1000vlk?ecd=bdc_podcast_libsyn_mscpedu